Resminostat also exhibited potent anti-HCC activity by activating the mitochondrial permeability transition pore (mPTP) dependent apoptosis pathway, which led to cytochrome C release and caspase-9 activation in HCC cell lines and primary HCC cells. This evidence concerns the gene CASP9 and hepatocellular carcinoma.